Esther Calbo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1317116/publications.pdf

Version: 2024-02-01

304743 243625 2,608 43 22 44 h-index citations g-index papers 47 47 47 3682 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Improvement of pneumococcal pneumonia diagnosis using quantitative real-time PCR targeting lytA in adult patients: a prospective cohort study. Clinical Microbiology and Infection, 2022, 28, 138.e1-138.e7.	6.0	5
2	Related Factors to Streptococcus pneumoniae Invasive Infection and Clinical Manifestations: The Potential Role of Nasopharyngeal Microbiome. Frontiers in Medicine, 2021, 8, 650271.	2.6	9
3	Applicability of Quality Indicators for Appropriate Antibiotic use in Outpatient Parenteral Antimicrobial Therapy (OPAT): A Point Prevalence Survey. Frontiers in Pharmacology, 2021, 12, 713882.	3.5	1
4	High clonal diversity of ESBL-producing Klebsiella pneumoniae isolates from clinical samples in a non-outbreak situation. A cohort study. Antimicrobial Resistance and Infection Control, 2020, 9, 5.	4.1	12
5	Applicability of Outpatient Quality Indicators for Appropriate Antibiotic Use in a Primary Health Care Area: a Point Prevalence Survey. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	1
6	Clinical and economic impact of bacterial resistance: an approach to infection control and antimicrobial stewardship solutions. Current Opinion in Infectious Diseases, 2020, 33, 458-463.	3.1	12
7	Genetic susceptibility to invasive pneumococcal disease. Infection, Genetics and Evolution, 2018, 59, 126-131.	2.3	10
8	Assessment of Quality Indicators for Appropriate Antibiotic Use. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	14
9	Emerging extended-spectrum β-lactamase-producing Klebsiella pneumoniae causing community-onset urinary tract infections: a case–control–control study. International Journal of Antimicrobial Agents, 2017, 50, 197-202.	2.5	21
10	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	2.5	8
11	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	5.8	43
12	ESGAP inventory of target indicators assessing antibiotic prescriptions: a cross-sectional survey. Journal of Antimicrobial Chemotherapy, 2017, 72, 2910-2914.	3.0	32
13	A Multinational, Preregistered Cohort Study of \hat{l}^2 -Lactam/ \hat{l}^2 -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum- \hat{l}^2 -Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169.	3.2	137
14	Molecular characterisation of acquired and overproduced chromosomal blaAmpC in Escherichia coli clinical isolates. International Journal of Antimicrobial Agents, 2016, 47, 62-68.	2.5	22
15	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	3.0	41
16	<i>Pseudomonas aeruginosa</i> Nosocomial Pneumonia: Impact of Pneumonia Classification. Infection Control and Hospital Epidemiology, 2015, 36, 1190-1197.	1.8	34
17	An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Critical Care, 2015, 19, 219.	5.8	209
18	Risk factors for severe sepsis in community-onset bacteraemic urinary tract infection: Impact of antimicrobial resistance in a large hospitalised cohort. Journal of Infection, 2015, 70, 247-254.	3.3	17

#	Article	IF	CITATIONS
19	Impact of vaccination on invasive pneumococcal disease in adults with focus on the immunosuppressed. Journal of Infection, 2015, 71, 422-427.	3.3	24
20	The changing epidemiology of hospital outbreaks due to ESBL-producing <i>Klebsiella pneumoniae</i> the CTX-M-15 type consolidation. Future Microbiology, 2015, 10, 1063-1075.	2.0	55
21	Influence of Virulence Genotype and Resistance Profile in the Mortality of Pseudomonas aeruginosa Bloodstream Infections. Clinical Infectious Diseases, 2015, 60, 539-548.	5.8	153
22	Epidemiology and risk factors for infections due to AmpC Â-lactamase-producing Escherichia coli. Journal of Antimicrobial Chemotherapy, 2015, 70, 899-904.	3.0	18
23	Effect of Adequate Single-Drug vs Combination Antimicrobial Therapy on Mortality in Pseudomonas aeruginosa Bloodstream Infections: A Post Hoc Analysis of a Prospective Cohort. Clinical Infectious Diseases, 2013, 57, 208-216.	5.8	135
24	A review of the factors influencing antimicrobial prescribing. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 12-15.	0.5	25
25	Hand contamination during routine care in medical wards: the role of hand hygiene compliance. Journal of Medical Microbiology, 2013, 62, 623-629.	1.8	14
26	Prospective Multicenter Study of the Impact of Carbapenem Resistance on Mortality in Pseudomonas aeruginosa Bloodstream Infections. Antimicrobial Agents and Chemotherapy, 2012, 56, 1265-1272.	3.2	123
27	Factors affecting the development of systemic inflammatory response syndrome in pneumococcal infections. Current Opinion in Infectious Diseases, 2011, 24, 241-247.	3.1	10
28	Procalcitonin levels are lower in intensive care unit patients with H1N1 influenza A virus pneumonia than in those with community-acquired bacterial pneumonia. A pilot study. Journal of Critical Care, 2011, 26, 201-205.	2.2	38
29	Foodborne Nosocomial Outbreak of SHV1 and CTX-M-15-producing Klebsiella pneumoniae: Epidemiology and Control. Clinical Infectious Diseases, 2011, 52, 743-749.	5.8	112
30	H1N1 influenza pneumonia and bacterial coinfection. Thorax, 2011, 66, 1091-1092.	5.6	2
31	The impact of time on the systemic inflammatory response in pneumococcal pneumonia. European Respiratory Journal, 2010, 35, 614-618.	6.7	30
32	Of mice and men: innate immunity in pneumococcal pneumonia. International Journal of Antimicrobial Agents, 2010, 35, 107-113.	2.5	59
33	Bacteraemic pneumococcal pneumonia in COPD patients: better outcomes than expected. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 971-976.	2.9	11
34	Community-acquired pneumonia. Lancet, The, 2008, 371, 455-458.	13.7	41
35	Systemic Expression of Cytokine Production in Patients with Severe Pneumococcal Pneumonia: Effects of Treatment with a \hat{I}^2 -Lactam versus a Fluoroquinolone. Antimicrobial Agents and Chemotherapy, 2008, 52, 2395-2402.	3.2	37
36	Capsular Types and Predicting Patient Outcomes in Pneumococcal Bacteremia. Clinical Infectious Diseases, 2007, 45, 52-54.	5.8	45

#	Article	IF	CITATION
37	Impact of amoxicillin, associated or not with clavulanic acid, on pharyngeal colonization and selection of Streptococcus pneumoniae resistance in children under 5 years of age. European Journal of Pediatrics, 2007, 166, 467-471.	2.7	7
38	Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum \hat{l}^2 -lactamases. Journal of Antimicrobial Chemotherapy, 2006, 57, 780-783.	3.0	261
39	Foreign-Body Osteoarticular Infection by Brucella melitensis: A Report of Three Cases. JBJS Case Connector, 2006, os-88, 202-204.	0.3	11
40	Application of Pharmacokinetics and Pharmacodynamics to Antimicrobial Therapy of Community-Acquired Respiratory Tract Infections. Respiration, 2005, 72, 561-571.	2.6	11
41	Invasive Pneumococcal Disease in Children: Changing Serotypes and Clinical Expression of Disease. Clinical Infectious Diseases, 2005, 41, 1821-1822.	5.8	14
42	Tromboembolia pulmonar y fiebre prolongada asociada a trombosis del electrodo del marcapasos. Medicina ClÃnica, 2004, 122, 759-759.	0.6	0
43	Mortality After Hospitalization for COPD. Chest, 2002, 121, 1441-1448.	0.8	582